AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA) 2026 Congress, a premier global gathering for hematologists and researchers, served as the stage for AvenCell Therapeutics to unveil compelling updated data from its Phase Ia RevSTAR-123 trial. The presentation, delivered on June 13, 2026, showcased the potential of AVC-201-01, a pioneering switchable allogeneic chimeric antigen receptor (CAR)-T cell therapy, in the challenging landscape of patients battling interleukin-3 receptor alpha chain (CD123)-positive relapsed/refractory (R/R) or minimal residual disease (MRD)-positive acute myeloid leukemia (AML). This development marks a significant step forward in the ongoing pursuit of more effective and adaptable cell-based treatments for this aggressive hematological malignancy.
Advancing CAR-T Therapy with an Innovative Allogeneic and Switchable Design
AVC-201-01 distinguishes itself through two critical and innovative design elements that address key limitations in current CAR-T therapy development. Firstly, it is an allogeneic product, meaning it is manufactured from T cells sourced from healthy donors rather than the patient’s own cells. This "off-the-shelf" approach holds immense promise for patients with R/R AML, a condition where time is of the essence. Many individuals with relapsed or refractory disease are unable to wait for the typically lengthy autologous CAR-T manufacturing process, which can take several weeks. Furthermore, patients who have undergone multiple prior lines of therapy, including chemotherapy and stem cell transplantation, may possess T cells of suboptimal quality for autologous CAR-T generation. The allogeneic nature of AVC-201-01 bypasses these hurdles, potentially offering a more readily available and robust therapeutic option.
Secondly, and perhaps most significantly, AVC-201-01 leverages AvenCell’s proprietary RevCAR platform. This innovative technology introduces a pharmacological "on-and-off" switch for CAR-T activation. Unlike conventional CAR-T therapies that rely on a continuously active, irreversible engagement with the target antigen, the RevCAR system requires a separately infused CD123-targeting module to activate the CAR-T cells. This switchable mechanism grants clinicians unprecedented control over CAR-T activity, allowing for modulation by simply adjusting the concentration or presence of the targeting module, rather than depending solely on the inherent persistence and activity of the CAR-T cells themselves.
This controlled activation is particularly crucial given the biological complexity of CD123 as a therapeutic target in AML. While CD123 is highly expressed on both leukemic blasts and the elusive leukemic stem cells (LSCs) that drive disease relapse, it is also found on normal hematopoietic progenitor cells and endothelial cells. This dual expression profile presents a significant challenge: targeting CD123 effectively to eliminate cancer cells without causing undue harm to essential healthy cells. The switchable nature of AVC-201-01 offers a potential solution to this delicate balancing act, enabling a more precise and potentially safer therapeutic window.
RevSTAR-123 Trial: Early Signals of Efficacy and Manageable Safety in a High-Risk Population
The updated findings from the RevSTAR-123 study provided an early yet meaningful signal of clinical activity within a particularly challenging patient cohort. The trial enrolled 17 patients diagnosed with R/R or MRD-positive CD123-positive AML. This population was heavily pre-treated, with a median of four prior lines of therapy. A substantial proportion of these patients, 10 out of 17, had previously undergone allogeneic hematopoietic stem cell transplant (allo-HSCT), a complex procedure often associated with increased treatment-related toxicity and limited subsequent therapeutic options. Furthermore, nine patients were classified as having adverse risk according to the European LeukemiaNet (ELN) classification, indicating a poorer prognosis and a higher likelihood of treatment failure.
From a safety perspective, the data demonstrated a manageable toxicity profile. Cytokine release syndrome (CRS), a common and potentially serious side effect of CAR-T therapy, occurred in 13 patients. However, the vast majority of these events were low-grade, with only one patient experiencing Grade 3 CRS. Crucially, there were no reported cases of immune effector cell-associated neurotoxicity syndrome (ICANS), a significant concern in CAR-T therapy. Moreover, the trial reported no instances of graft-versus-host disease (GvHD), a serious complication that can arise after allo-HSCT, and no treatment-related mortality was observed. A single dose-limiting toxicity (DLT) was identified at the highest dose level tested, providing valuable information for dose escalation and optimization in future studies.
In terms of efficacy, the most promising results were observed at higher dose levels. Among the eight evaluable patients at dose level 12 (DL12) and dose level 15 (DL15), three achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh). Notably, two of these responders achieved MRD-negative complete remissions, indicating a deep and potentially durable eradication of leukemia cells. These early efficacy signals, coupled with the manageable safety profile, offer strong initial validation for AvenCell’s switchable allogeneic CD123 CAR-T platform.
Navigating the Competitive Relapsed/Refractory AML Market
Should AVC-201-01 successfully navigate the rigorous path of further clinical development and regulatory approval, it would enter a dynamic and evolving relapsed/refractory AML market. This market has been significantly shaped by the advent of biomarker-selected targeted therapies and the increasing integration of novel cellular approaches.
A key commercial benchmark in this space is Astellas’ Xospata (gilteritinib). Approved as an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor, Xospata offers a significant benefit to patients with FLT3-mutated R/R AML. Its advantages include outpatient administration and robust Phase III survival validation, establishing it as a standard of care for its specific patient subgroup. However, its application is confined to a molecularly defined patient population, highlighting the unmet need for treatments that can benefit a broader spectrum of R/R AML patients.
In contrast, AVC-201-01 holds the potential for broader applicability, targeting CD123 expression, which is present in a larger proportion of AML patients, including those without actionable mutations like FLT3. For AVC-201-01 to truly differentiate itself and justify the complexity of a cellular therapy, it will need to demonstrate not only durable MRD conversion but also a manageable toxicity profile and the ability to effectively bridge patients to potentially curative treatments like allogeneic stem cell transplantation.
The therapeutic landscape is further informed by AbbVie’s Decnupaz (pivekimab sunirine), a CD123-directed antibody-drug conjugate (ADC). While Decnupaz has received approval for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in a Phase III study (REVIVAL) for AML, its progress reinforces CD123 as a clinically validated and highly relevant target in myeloid malignancies. AVC-201-01’s distinct advantage lies in its switchable allogeneic CAR-T design. Its ultimate value proposition will hinge on its ability to deliver deeper and more sustained remissions compared to non-cellular CD123-directed therapies, thereby offering a superior clinical outcome for patients.
Commercial Outlook and Future Prospects: A Promising Concept in Early Validation
From a commercial perspective, AVC-201-01 presents an attractive proposition, albeit one that remains at a high risk given its early stage of development. The allogeneic format offers a significant potential advantage by shortening manufacturing timelines and enhancing scalability. This is particularly critical in the context of rapidly progressing R/R AML, where prompt intervention is paramount. Furthermore, the switchable CD123 targeting module, enabled by the RevCAR platform, could provide a crucial safety and dosing advantage within a narrow therapeutic window, allowing for more precise control over treatment intensity and minimizing off-target effects.
However, the widespread adoption and clinical success of AVC-201-01 will ultimately depend on the generation of clear and compelling evidence. This evidence must encompass deeper responses, consistent MRD negativity, durable remissions, and a demonstrably manageable profile of CRS and other cytopenias. Additionally, its ability to effectively serve as a bridge to transplant will be a critical factor in its therapeutic positioning.
In summary, AVC-201-01 should be viewed as an early and encouraging validation of a next-generation AML CAR-T concept. While the presented data are promising and highlight the innovative potential of AvenCell’s platform, it is not yet a practice-changing therapy. Further clinical investigation, including larger Phase II and Phase III trials, will be essential to fully elucidate its efficacy, safety, and long-term benefits, paving the way for its potential integration into the treatment paradigms for relapsed/refractory AML. The scientific community and patient advocates will be closely monitoring the progress of AVC-201-01 as it moves through its development pipeline, hopeful that this novel approach will translate into improved outcomes for those facing this formidable disease.
